Clinical trials: Advanced Hepatocellular Carcinoma
Advanced Hepatocellular Carcinoma
Phase I/II Study of Amplitude-Modulated Electromagnetic Fields in the Treatment of Advanced Hepatocellular Carcinoma
The goal of this study is to investigate the safety and feasibility of treating patients with advanced hepatocellular carcinoma with a noninvasive device administering low level of amplitude-modulated electromagnetic fields.
- Trial name
- TheraBionic (NCT00534664)
- Testing
- TheraBionic device
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- University of Sao Paulo
Hepatocellular Carcinoma
Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer
The goal of this clinical trial is to evaluate the efficacy and safety of cardonilizumab injection combined with TKI in second-line treatment of advanced hepatocellular carcinoma.
- Trial name
- NCT06363006
- Testing
- TKI+Cardunilimab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Hepatocellular Carcinoma
The ImmunoXXL Study
This study is aimed at confirming data of efficacy and safety of liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) beyond current transplant criteria who demonstrate a sustained partial or complete…
- Trial name
- ImmunoXXL (NCT05879328)
- Testing
- Liver Transplantation
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Hepatocellular Carcinoma
Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma
The purpose of this study is to investigate both the efficacy and safety of sintilimab combined with bevacizumab and radiotherapy in advanced hepatocellular carcinoma.
- Trial name
- NCT05010434
- Testing
- Sintilimab and Bevacizumab Combined with Radiotherapy
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of sorafenib combined with hepatic arterial infusion chemotherapy (HAIC) compared with sorafenib Alone in patients with hepatocellular carcinoma (HCC) with major…
- Trial name
- NCT02774187
- Testing
- Sorafenib, Hepatic arterial infusion chemotherapy, Folfox Protocol
- Where
- 5 sites in China
- Volunteers
- 247 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Hepatocellular
A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib
This study evaluate activity and safety profile of weekly Genexol-PM in patients with advanced hepatocellular carcinoma for whom sorafenib treatment failed. Patients will receive Genexol-PM on days 1, 8, and 15 every 4 weeks.
- Trial name
- NCT03008512
- Testing
- Genexol-PM
- Where
- 2 sites in South Korea
- Volunteers
- 5 people
- Sponsor
- Gachon University Gil Medical Center
Hepatocellular Carcinoma
Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC
To investigate efficacy and toxicity of regorafenib after treatment with atezolizumab and bevacizumab combination
- Trial name
- HCC (NCT05134532)
- Testing
- regorafenib
- Where
- 2 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- CHA University
Liver Cancer, Metastatic Cancer
Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor.
- Trial name
- NCT00003907
- Testing
- cisplatin, doxorubicin, mitomycin
- Where
- 37 sites in United States
- Volunteers
- 50 people
- Sponsor
- Eastern Cooperative Oncology Group
Primary Hepatocellular Carcinoma
Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma
VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 injection.This study will be conducted in combination with camrelizumab in patients with advanced advanced primary hepatocellular carcinoma who have received at least one…
- Trial name
- NCT06124001
- Testing
- Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), camrelizumab for Injection
- Volunteers
- 36 people
- Sponsor
- CNBG-Virogin Biotech (Shanghai) Ltd.
Liver Cancer
Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
To learn if giving immune checkpoint therapy (such as atezolizumab) and bevacizumab to patients who have HCC and are receiving DAAs may help to control HCC and hepatitis C.
- Trial name
- NCT05717400
- Testing
- Bevacizumab, Atezolizumab, Sofosbuvir
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Liver Cancer
DX-8951f in Treating Patients With Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have liver cancer.
- Trial name
- NCT00004108
- Testing
- exatecan mesylate
- Where
- 4 sites in United States
- Sponsor
- Daiichi Sankyo
Advanced Hepatocellular Carcinoma
Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma
A Phase I Clinical Study of CT0181 cells in Patients with Advanced Hepatocellular Carcinoma
- Trial name
- NCT04973098
- Testing
- CT0181 Cells
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Peking University
Hepatocellular Carcinoma, Liver Cancer
A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
The purpose of this clinical research study is to learn about the safety and effectiveness of cabozantinib and nivolumab in people with hepatocellular carcinoma (HCC).
- Trial name
- NCT05039736
- Testing
- Cabozantinib, Nivolumab
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer, Depression
Studying Pain and Symptom Distress in Patients With Advanced Colon Cancer, Rectal Cancer, Pancreatic Cancer, or Liver Cancer
RATIONALE: Studying a patient's understanding of his or her illness, pain, symptoms, and quality-of-life may help the study of advanced cancer and may help patients live more comfortably.
- Conditions
- Colorectal Cancer, Depression, Fatigue, Liver Cancer
- Trial name
- NCT00950144
- Testing
- medical chart review, questionnaire administration, study of socioeconomic and demographic variables
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- City of Hope Medical Center
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
The main purpose of this study is to evaluate the safety of ramucirumab plus MEDI4736 in participants with locally advanced and unresectable or metastatic gastrointestinal or thoracic malignancies including gastric or…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
- Trial name
- NCT02572687
- Testing
- Ramucirumab, MEDI4736
- Where
- 28 sites in United States, France and 6 more
- Volunteers
- 85 people
- Sponsor
- Eli Lilly and Company
Hepatocellular Carcinoma
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
This is an open-label, multicenter, Phase I/II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of MRG006A in combination with immune checkpoint inhibitors and targeted…
- Trial name
- NCT07479485
- Testing
- MRG006A, Pucotenlimab, Bevacizumab
- Where
- 8 sites in China
- Volunteers
- 160 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Hepatocellular Carcinoma
Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC)
The mTOR has been examined in hepatocellular carcinomas as well. This pathway is up-regulated in a proportion of hepatocellular carcinoma (HCC) and that rapamycin inhibits cell proliferation and blocks S6K phosphorylation.
- Trial name
- NCT00390195
- Testing
- RAD001 (everolimus)
- Where
- 2 sites in Taiwan
- Volunteers
- 134 people
- Sponsor
- National Health Research Institutes, Taiwan
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Intravenous VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.
- Trial name
- NCT00082823
- Testing
- ziv-aflibercept
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
HCC - Hepatocellular Carcinoma
The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
This research plan involves a treatment approach for advanced hepatocellular carcinoma (HCC) in the context of metabolic-associated steatotic liver disease (MASLD).
- Trial name
- ABATE-MASLD (NCT07285850)
- Testing
- Sequential treatment of bevacizumab combined with atezolizumab (sequential group), Simultaneous treatment of bevacizumab combined with atezolizumab (same period group)
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.